High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery. In this whitepaper, “Disrupting Drug Discovery From Assay Development to Lead Compound”, SAMDI Tech CSO, Zack Gurard-Levin, discusses the important aspects to consider when choosing the right methodology for drug discovery.
The whitepaper covers traditional label-dependent approaches versus novel label-free technologies; how researchers determine which methodology offers the most promising path forward for their target; how to take into account assay sensitivity, data quality, costs, and speed; and when to outsource to contract research organisations with an established discovery infrastructure to lead hit identification and hit-to-lead programs.
Download the whitepaper here.
